Dinglasan, Nuntana

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 369

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 264

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Koltun, E. S., Rice, M. A., Gustafson, W. C., Wilds, D., Jiang, J., Lee, B. J., Wang, Z., Chang, S., Flagella, M., Mu, Y., et al. (2022) · Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 34

Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.

Gustafson, W. C., Wildes, D., Rice, M. A., Lee, B. J., Jiang, J., Wang, Z., Chang, S., Flagella, M., Mu, Y., Dinglasan, N., et al. (2022) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingPancreatic and Hepatic Oncology Research

Cited by 28